Dendritic-cell-based therapeutic vaccination against cancer

Current Opinion in Immunology

Volumn 17, Issue 2, 2005, Pages 163-169

  Nestle, Frank O ^a   Farkas, Arpad ^a   Conrad, Curdin ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD34 ANTIGEN; CD40 LIGAND; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

B LYMPHOCYTE; CANCER; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HUMAN; LYMPHOID TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX; REVIEW; STANDARD; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; VACCINATION;

EID: 14844331400     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2005.02.003     Document Type: Review

References (67)

1. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
2. R.M. Zinkernagel Localization dose and time of antigens determine immune reactivity Semin Immunol 12 2000 163 171 discussion 257-344
3. th International Expert Meeting on Clinical Dendritic Cell Therapy in Amsterdam. Extensive supplementary tables provide a good overview of currently ongoing DC vaccination trials.
4. C.J. Turtle, and D.N. Hart Dendritic cells in tumor immunology and immunotherapy Curr Drug Targets 5 2004 17 39
5. E.G. Engleman Dendritic cell-based cancer immunotherapy Semin Oncol 30 2003 23 29
6. D.H. Chang, and M.V. Dhodapkar Dendritic cells and immunotherapy for cancer Int J Hematol 77 2003 439 443
7. G. Schuler, B. Schuler-Thurner, and R.M. Steinman The use of dendritic cells in cancer immunotherapy Curr Opin Immunol 15 2003 138 147
8. D.W. O'Neill, S. Adams, and N. Bhardwaj Manipulating dendritic cell biology for the active immunotherapy of cancer Blood 104 2004 2235 2246
9. C. Conrad, and F.O. Nestle Dendritic cell-based cancer therapy Curr Opin Mol Ther 5 2003 405 412
10. F.O. Nestle, J. Banchereau, and D. Hart Dendritic cells: On the move from bench to bedside Nat Med 7 2001 761 765
11. D. Ridgway The first 1000 dendritic cell vaccinees Cancer Invest 21 2003 873 886
12. R.M. Steinman, and I. Mellman Immunotherapy: bewitched, bothered, and bewildered no more Science 305 2004 197 200
13. D. Pardoll, and J. Allison Cancer immunotherapy: breaking the barriers to harvest the crop Nat Med 10 2004 887 892 Together with [12], this key paper discusses the demands of human research, including cancer immunotherapy, and calls for better support of the academic investigator as they navigate the pathways from laboratory to clinic.
14. S. Adams, D. O'Neill, and N. Bhardwaj Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines J Clin Oncol 22 2004 3834 3835 author reply 3835
15. M. Smithers, K. O'Connell, S. MacFadyen, M. Chambers, K. Greenwood, A. Boyce, I. Abdul-Jabbar, K. Barker, K. Grimmett, and E. Walpole Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen Cancer Immunol Immunother 52 2003 41 52
16. Z. Su, J. Dannull, A. Heiser, D. Yancey, S. Pruitt, J. Madden, D. Coleman, D. Niedzwiecki, E. Gilboa, and J. Vieweg Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells Cancer Res 63 2003 2127 2133
17. P. Kalinski, P.L. Vieira, J.H. Schuitemaker, E.C. de Jong, and M.L. Kapsenberg Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer Blood 97 2001 3466 3469
18. A. Langenkamp, M. Messi, A. Lanzavecchia, and F. Sallusto Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells Nat Immunol 1 2000 311 316
19. O. Tureci, H. Bian, F.O. Nestle, L. Raddrizzani, J.A. Rosinski, A. Tassis, H. Hilton, M. Walstead, U. Sahin, and J. Hammer Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis FASEB J 17 2003 836 847 This paper demonstrates the plasticity of DC differentiation on the transcriptome level, emphasizing the importance of timing of the maturation stimuli.
20. J.A. Lopez, G. Bioley, C.J. Turtle, A. Pinzon-Charry, C.S. Ho, S. Vuckovic, G. Crosbie, M. Gilleece, D.C. Jackson, and D. Munster Single step enrichment of blood dendritic cells by positive immunoselection J Immunol Methods 274 2003 47 61
21. J.M. Timmerman, D.K. Czerwinski, T.A. Davis, F.J. Hsu, C. Benike, Z.M. Hao, B. Taidi, R. Rajapaksa, C.B. Caspar, and C.Y. Okada Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood 99 2002 1517 1526
22. L. Fong, Y. Hou, A. Rivas, C. Benike, A. Yuen, G.A. Fisher, M.M. Davis, and E.G. Engleman Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy Proc Natl Acad Sci USA 98 2001 8809 8814
23. J. Banchereau, A.K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K.M. Wittkowski, and N. Bhardwaj Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine Cancer Res 61 2001 6451 6458
24. S. Paczesny, J. Banchereau, K.M. Wittkowski, G. Saracino, J. Fay, and A.K. Palucka Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells J Exp Med 199 2004 1503 1511
25. A.K. Palucka, M.V. Dhodapkar, S. Paczesny, S. Burkeholder, K.M. Wittkowski, R.M. Steinman, J. Fay, and J. Banchereau Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma J Immunother 26 2003 432 439
26. S. Hori, Y. Heike, M. Takei, M. Maruyama, Y. Inoue, J.J. Lee, H.J. Kim, Y. Harada, H. Kawai, and A. Shimosaka Freeze-thawing procedures have no influence on the phenotypic and functional development of dendritic cells generated from peripheral blood CD14+ monocytes J Immunother 27 2004 27 35
27. J. Westermann, I.J. Korner, J. Kopp, S. Kurz, M. Zenke, B. Dorken, and A. Pezzutto Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties Cancer Immunol Immunother 52 2003 194 198
28. I.J. de Vries, A.A. Eggert, N.M. Scharenborg, J.L. Vissers, W.J. Lesterhuis, O.C. Boerman, C.J. Punt, G.J. Adema, and C.G. Figdor Phenotypical and functional characterization of clinical grade dendritic cells J Immunother 25 2002 429 438
29. Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, Vuk-Pavlovic S: Clinical-grade manufacturing of DC from CD14 precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy in press.
30. L.J. Mu, G. Gaudernack, S. Saeboe-Larssen, H. Hammerstad, A. Tierens, and G. Kvalheim A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines Scand J Immunol 58 2003 578 586
31. S. Tuyaerts, S.M. Noppe, J. Corthals, K. Breckpot, C. Heirman, C. De Greef, I. Van Riet, and K. Thielemans Generation of large numbers of dendritic cells in a closed system using Cell Factories J Immunol Methods 264 2002 135 151
32. R.V. Sorg, Z. Ozcan, T. Brefort, J. Fischer, R. Ackermann, M. Muller, and P. Wernet Clinical-scale generation of dendritic cells in a closed system J Immunother 26 2003 374 383
33. C.M. Celluzzi, and C. Welbon Dendritic cell culture: a simple closed culture system using ficoll, monocytes, and a table-top centrifuge J Hematother Stem Cell Res 12 2003 575 585
34. V. Pullarkat, R. Lau, S.M. Lee, J.G. Bender, and J.S. Weber Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells J Immunol Methods 267 2002 173 183
35. P. Romero, J.C. Cerottini, and D.E. Speiser Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination Cancer Immunol Immunother 53 2004 249 255 Essential reading on the state of the art of immune monitoring.
36. R.S. Goldszmid, J. Idoyaga, A.I. Bravo, R. Steinman, J. Mordoh, and R. Wainstok Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma J Immunol 171 2003 5940 5947
37. Y. Waeckerle-Men, E. Scandella, E. Uetz-Von Allmen, B. Ludewig, S. Gillessen, H.P. Merkle, B. Gander, and M. Groettrup Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy J Immunol Methods 287 2004 109 124
38. M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G.F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, and P. Chaplin Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma Clin Cancer Res 10 2004 5381 5390
39. M. Dullaers, K. Breckpot, S. Van Meirvenne, A. Bonehill, S. Tuyaerts, A. Michiels, L. Straetman, C. Heirman, C. De Greef, and P. Van Der Bruggen Side-by-side comparison of lentivirally transduced and MRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols Mol Ther 10 2004 768 779
40. F.O. Nestle, S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med 4 1998 328 332
41. I. Bedrosian, R. Mick, S. Xu, H. Nisenbaum, M. Faries, P. Zhang, P.A. Cohen, G. Koski, and B.J. Czerniecki Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients J Clin Oncol 21 2003 3826 3835 This is the first paper to compare, in a comprehensive fashion, intranodal, intradermal and intravenous injection of mature DCs into cancer patients.
42. I.J. de Vries, W.J. Lesterhuis, N.M. Scharenborg, L.P. Engelen, D.J. Ruiter, M.J. Gerritsen, S. Croockewit, C.M. Britten, R. Torensma, and G.J. Adema Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients Clin Cancer Res 9 2003 5091 5100
43. S. Nair, C. McLaughlin, A. Weizer, Z. Su, D. Boczkowski, J. Dannull, J. Vieweg, and E. Gilboa Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation J Immunol 171 2003 6275 6282
44. A. MartIn-Fontecha, S. Sebastiani, U.E. Hopken, M. Uguccioni, M. Lipp, A. Lanzavecchia, and F. Sallusto Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming J Exp Med 198 2003 615 621 Together with [43], this paper introduces the concept of 'in situ maturation' of dendritic cells.
45. Y. Satoh, C. Esche, A. Gambotto, G.V. Shurin, Z.R. Yurkovetsky, P.D. Robbins, S.C. Watkins, S. Todo, R.B. Herberman, and M.T. Lotze Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice J Exp Ther Oncol 2 2002 337 349
46. R. Yamanaka, N. Tsuchiya, N. Yajima, J. Honma, H. Hasegawa, R. Tanaka, J. Ramsey, R.M. Blaese, and K.G. Xanthopoulos Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12 J Neurosurg 99 2003 746 753
47. M. Ehtesham, P. Kabos, M.A. Gutierrez, K. Samoto, K.L. Black, and J.S. Yu Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats J Immunother 26 2003 107 116
48. V. Cerundolo, I.F. Hermans, and M. Salio Dendritic cells: a journey from laboratory to clinic Nat Immunol 5 2004 7 10
49. C.L. Slingluff Jr., G.R. Petroni, G.V. Yamshchikov, D.L. Barnd, S. Eastham, H. Galavotti, J.W. Patterson, D.H. Deacon, S. Hibbitts, and D. Teates Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells J Clin Oncol 21 2003 4016 4026
50. + T cells in melanoma patients.
51. D. Godelaine, J. Carrasco, S. Lucas, V. Karanikas, B. Schuler-Thurner, P.G. Coulie, G. Schuler, T. Boon, and A. Van Pel Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide J Immunol 171 2003 4893 4897
52. C.M. Smith, N.S. Wilson, J. Waithman, J.A. Villadangos, F.R. Carbone, W.R. Heath, and G.T. Belz Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity Nat Immunol 5 2004 1143 1148
53. E.S. Schultz, B. Schuler-Thurner, V. Stroobant, L. Jenne, T.G. Berger, K. Thielemanns, P. van der Bruggen, and G. Schuler Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy J Immunol 172 2004 1304 1310
54. M. Gilliet, M. Kleinhans, E. Lantelme, D. Schadendorf, G. Burg, and F.O. Nestle Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen Blood 102 2003 36 42 First human in vivo study providing a detailed analysis of the helper T cell response occurring after intranodal injection of neo-protein (i.e. keyhole limpet hemocyanin) pulsed DCs.
55. C. Borg, M. Terme, J. Taieb, C. Menard, C. Flament, C. Robert, K. Maruyama, H. Wakasugi, E. Angevin, and K. Thielemans Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects J Clin Invest 114 2004 379 388
56. S. Fujii, K. Shimizu, M. Kronenberg, and R.M. Steinman Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs Nat Immunol 3 2002 867 874
57. S. Fujii, K. Shimizu, R.M. Steinman, and M.V. Dhodapkar Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells J Immunol Methods 272 2003 147 159
58. M. Nieda, M. Okai, A. Tazbirkova, H. Lin, A. Yamaura, K. Ide, R. Abraham, T. Juji, D.J. Macfarlane, and A.J. Nicol Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity Blood 103 2004 383 389
59. L.C. Bonifaz, D.P. Bonnyay, A. Charalambous, D.I. Darguste, S. Fujii, H. Soares, M.K. Brimnes, B. Moltedo, T.M. Moran, and R.M. Steinman In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination J Exp Med 199 2004 815 824 This key study defines for the first time the requirements of DC targeting using DEC-205 for T-cell vaccination.
60. V. Ramakrishna, J.F. Treml, L. Vitale, J.E. Connolly, T. O'Neill, P.A. Smith, C.L. Jones, L.Z. He, J. Goldstein, and P.K. Wallace Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules J Immunol 172 2004 2845 2852
61. C.J. Melief, S.H. Van Der Burg, R.E. Toes, F. Ossendorp, and R. Offringa Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes Immunol Rev 188 2002 177 182
62. K. Furumoto, L. Soares, E.G. Engleman, and M. Merad Induction of potent antitumor immunity by in situ targeting of intratumoral DCs J Clin Invest 113 2004 774 783
63. T. Maier, A. Tun-Kyi, A. Tassis, K.P. Jungius, G. Burg, R. Dummer, and F.O. Nestle Vaccination of cutaneous T-cell lymphoma patients using intranodal injection of autologous tumor lysate pulsed dendritic cells Blood 102 2003 2338 2344 This is the first demonstration of clinical as well as immunological responses in selected patients with cutaneous T-cell lymphoma (CTCL). CTCL is an interesting tumor for vaccination therapy due to its slow course, the clearly visible skin tumors and defined molecular endpoints. This tumor allows the unique opportunity to establish a correlation between vaccine application and tumor response.
64. S. Nair, D. Boczkowski, B. Moeller, M. Dewhirst, J. Vieweg, and E. Gilboa Synergy between tumor immunotherapy and antiangiogenic therapy Blood 102 2003 964 971 The authors of this study introduce the concept of combining tumor immunotherapy with anti-angiogenic therapy using RNA-pulsed DCs.
65. W. Asavaroengchai, Y. Kotera, and J.J. Mule Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery Proc Natl Acad Sci USA 99 2002 931 936
66. F.S. Hodi, M.C. Mihm, R.J. Soiffer, F.G. Haluska, M. Butler, M.V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, and A. Willman Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci USA 100 2003 4712 4717 This is a key paper showing the biological effects, in previously vaccinated cancer patients (including patients vaccinated with DCs) of CTLA-4 antibody blockade.
67. R.P. Sutmuller, R. Offringa, and C.J. Melief Revival of the regulatory T cell: new targets for drug development Drug Discov Today 9 2004 310 316